Hitherto no therapeutic has received regulatory approval for the treatment of post-COVID-19
condition (PCC). Cognitive deficits, mood symptoms and significant reduction in health …

Aim Major depressive disorder (MDD) is a prevalent psychiatric condition and vortioxetine
offers promising antidepressant effects due to its unique pharmacological profile. However …

The surveillance search since the inaugural review was published covers the search
periods from 8 August 2022 to 22 August 2023. To inform the surveillance search, we …

Background Functional impairment is common in patients with major depressive disorder
(MDD). The Functioning Assessment Short Test (FAST) provides a detailed clinician-rated …

The first update alert found 2 newly published randomized controlled trials (RCTs), 1
addressing key question (KQ) 1 (art therapy vs. second-generation antidepressant [SGA] for …

Background The multinational, open-label COMPLETE study (NCT03835715) investigated
the effectiveness of vortioxetine in alleviating emotional blunting in patients with major …

Background Although vortioxetine demonstrates superior efficacy relative to placebo, there
is still a lack of robust evidence to determine whether it offers advantages over commonly …

Depressive symptoms are a customary finding in hospitalized patients, particularly those
who are undergoing long hospitalizations, underwent major surgical procedures or suffer …

Background Major depressive disorder (MDD) causes significant functional impairments that
impact on all aspects of patients' daily lives, including their ability to work, work productivity …

Background: Vortioxetine is efficacious and well tolerated in patients with major depressive
disorder (MDD) and is available as an immediate-release tablet and oral drop solution. The …